Neoantigen × AI
Daily research signal
№55Brief

Shared driver neoantigens become credible complement to personalized vaccines

Today's items converge on a key strategic question in neoantigen therapy: shared, driver-derived antigens versus fully personalized constructs.

A CALR-mutant neoantigen common across ET and myelofibrosis subgroups opens an off-the-shelf path in myeloproliferative neoplasms, while preclinical mRNA-LNP data in EGFRvIII-driven glioblastoma show how vaccination can remodel an immunosuppressive microenvironment.OncodailybioRxiv Both suggest shared driver antigens, paired with mechanistic spatial biology, are becoming a credible complement to individualized vaccine programs.OncodailybioRxiv

2new stories
ClinicalyesterdayNew

CALR-Mutated MPN: A Shared Neoantigen Makes Immunotherapy Possible, and Antibodies Lead So Far - Oncodaily

Oncodaily reviews the immunotherapy case for CALR-mutated essential thrombocythemia and primary myelofibrosis, where the type 1 (52-bp deletion) and type 2 (5-bp insertion) exon 9 variants both yield the same 36-amino-acid neomorphic C-terminal sequence absent from wild-type calreticulin. Because mutant CALR drives disease by binding and activating MPL independently of thrombopoietin, and mutant CALR-MPL complexes reach the cell surface, this shared driver neoantigen is targetable by vaccines, monoclonal and bispecific antibodies, and engineered T cells. For investors, the signal is a shared-antigen, off-the-shelf opportunity in a defined molecular MPN subgroup; per the piece, antibodies currently lead the field, with vaccines and cell therapies behind.

news · yesterday · Oncodaily

01

01
ClinicalyesterdayNew

mRNA-LNP vaccination induces microenvironment remodeling and generation of tissue-resident memory T cells in glioblastoma

A preclinical biorxiv study in an immunocompetent EGFRvIII-driven syngeneic glioblastoma model shows antigen-specific mRNA-LNP vaccination induced durable EGFRvIII-specific humoral and cellular immunity, complete tumor eradication, and long-term protection against intracranial rechallenge. Multi-modal profiling (flow cytometry, tumor interstitial fluid, multiplex immunostaining, spatial transcriptomics, ligand-receptor modeling) tied response to expansion of pro-inflammatory, antigen-presenting myeloid populations, increased cytotoxic CD8 infiltration and activation, enhanced interferon signaling, and generation of tissue-resident memory T cells. The takeaway for the field: mechanistic evidence that mRNA-LNP vaccines can remodel the GBM microenvironment, not just elicit T cells, supporting translation of shared-antigen mRNA platforms into one of immunotherapy's most refractory indications.

biorxiv · yesterday · Snelling, S. M.; Manoharan, V. T.; Pyczek, J.; Lun, X.; Wang, J.; Liu, J.; Gold, M. J.; Ne